Zassi Bowel Management Systems

Starting point, 2002

Zassi Bowel Management Systems, a US manufacturer of bowel management systems for intensive care, was looking to enter the German market in 2002. The starting position was typical for an explanation-intensive US product: no German GmbH, no clinical evidence from a German setting, no sales base in the DACH region, no established KOL network.

The conventional routes would have been:

• Find a German distributor and agree on a commission model — the product would have been listed as one position among hundreds, with no priority.
• Set up a German subsidiary — a six-figure initial investment against an unvalidated market, and therefore a high risk.
• Commission clinical studies first — typically 18 to 24 months with no sales result.

MEX chose a fourth route.

Phase 1 — Pre-sale and KOL test (2002)

Rather than handing the product to a distributor, MEX set up a clinical test at Göttingen University Hospital, Germany’s fifth-largest hospital. The test was not a formal study protocol but a pragmatic introduction into everyday clinical practice, supported by the MEX sales network of the time.

Establishing a KOL in Göttingen served three purposes at once:

• It validated the product’s clinical differentiation under real conditions.
• It created a visible reference KOL for subsequent hospital listings.
• It produced the evidence base for a premium pricing strategy rather than a volume strategy.

That premium pricing strategy was contested in the US home market. In Germany it became the precondition for the product not being filed into the same comparison class as cheaper alternatives.

Phase 2 — Initial sales and scale-up (2003–2005)

The Göttingen KOL test became the starting point for a stepwise roll-out through the MEX sales network. University hospitals came first, then maximum-care hospitals, then larger hospital groups. Every hospital was approached with the Göttingen data point and a specific clinical use case — not with a product catalog.

In parallel, MEX built the client’s German GmbH infrastructure:

• A client GmbH as the German legal entity, with MEX providing the managing director.
• Contractual relationships with Einkaufsgemeinschaften (Germany’s hospital group purchasing organizations) and hospital groups.
• A vigilance and complaints pipeline under the medical device rules then in force — the predecessor regime to today’s MDR.
• Training materials and user training for clinical staff, delivered by the field force and the Board of Experts.

Phase 3 — Top sales market in Europe (2005)

Three years after the first KOL engagement, Germany was by a wide margin Zassi’s strongest sales market in Europe — at twenty times the volume of the next-best European market.

The German hospital market rewards clinically differentiated products that are introduced with the right listing strategy, KOL support and sales structure.

The factor-20 gap was not a marketing success. It was the result of a structured roadmap: KOL test first, clinical validation at a top-five hospital, stepwise roll-out through a dedicated sales network, premium pricing instead of price competition.

Phase 4 — Strategic trade sale (2008)

After three years of successful commercialization in more than twenty countries, Zassi was sold to Hollister, Inc., a global healthcare company focused on ostomy, continence and critical care products. At that point the German market was the most profitable and strategically most valuable contributor to Zassi’s valuation.

MEX supported the transition operationally, not just transactionally: customer onboarding and training in the DACH region continued for Hollister. The hospital relationships remained intact and the vigilance pipeline migrated into Hollister’s structures without a break.

Phase 5 — Post-sale support (2008 onwards)

The sale ended the classic market entry mandate. What began instead was a transition mandate: Hollister wanted to take over the hospital relationships and the KOL network but had no in-house people with the specific product expertise and the language of German hospitals. MEX took on training, customer onboarding and selective account management — over several quarters, winding down in a controlled way.

That completed the first fully documented MEX arc:

Pre-sale test → initial sales → scale-up → trade sale → post-sale support.

This arc has been the strategic frame for every market entry MEX plans since — from the first KOL conversation to a possible handover to an industrial buyer.

Lessons for other MedTech manufacturers

Three points from the Zassi mandate transfer to other foreign MedTech manufacturers in the German hospital market:

• A KOL test beats a distributor. A clinical test at a top-five university hospital produces validation and visibility that no distributor agreement can generate.
• Premium pricing requires clinical evidence. Without documented clinical differentiation, any product ends up in the price class of its cheapest alternative.
• Trade sale potential grows out of German market share. Becoming the EU leader in Germany multiplies the acquisition value back in the US home market.

If you want to know whether an arc comparable to Zassi’s is realistic for your product, arrange a 30-minute discovery call — we will review product category, clinical differentiation, KOL setting and possible roadmap options.